Substance / Medication

Quinacrine

Overview

Active Ingredient
quinacrine
RxNorm CUI
9061

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease.
Geschwind Michael D, Kuo Amy L, Wong Katherine S et al. · Neurology · 2013
PMID: 24122181RCTFull text (PMC)
First-in-Human Phase 1b Trial of Quinacrine Plus Capecitabine in Patients With Refractory Metastatic Colorectal Cancer.
Winer Arthur, Denlinger Crystal S, Vijayvergia Namrata et al. · Clin Colorectal Cancer · 2021
PMID: 32972830Trial
Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancer.
Bhateja Priyanka, Dowlati Afshin, Sharma Neelesh · Invest New Drugs · 2018
PMID: 28971268Trial
Quinacrine sterilization for human immunodeficiency virus-positive women.
de Magalhães Déborah Randazzo Barbosa, de Carvalho Ferreira Cláudia Ramos, Barbosa Magalhães Estefânia et al. · Fertil Steril · 2009
PMID: 18973884Trial
Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial.
Collinge John, Gorham Michele, Hudson Fleur et al. · Lancet Neurol · 2009
PMID: 19278902TrialFull text (PMC)
A possible pharmacological explanation for quinacrine failure to treat prion diseases: pharmacokinetic investigations in a ovine model of scrapie.
Gayrard Véronique, Picard-Hagen Nicole, Viguié Catherine et al. · Br J Pharmacol · 2005
PMID: 15655516TrialFull text (PMC)
Results of quinacrine administration to patients with Creutzfeldt-Jakob disease.
Nakajima Masashi, Yamada Tatsuo, Kusuhara Tomohiko et al. · Dement Geriatr Cogn Disord · 2004
PMID: 14739538Trial
Quinacrine added to ongoing therapeutic regimens attenuates anticardiolipin antibody production in SLE.
Toubi E, Kessel A, Rosner I et al. · Lupus · 2003
PMID: 12729053Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Mepacrine (substance)
SNOMED CT
387445007
UMLS CUI
C0034403
RxNorm CUI
9061

Clinical Data

This intervention maps to 3 entities in the Ltrl knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.